Fletcher et al. developed a TRIM21-based PROTAC to degrade Human antigen R (HuR), an RNA regulator, to inhibit tumor growth in pre-clinical models by regulating HuR-related biological process. This evidence concerns the gene ELAVL1 and neoplasm.